🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In a study led by Dr. MLK Chua & team, a deep learning model shows promise in transforming how we assess tumor-infiltrating lymphocytes (TILs) in nasopharyngeal carcinoma (NPC). Using H&E-stained slides, this AI-driven approach (TILDL) accurately quantifies TILs, predicting

Microsoft claims AI diagnostic tool can outperform doctors Research is first initiative from Big Tech group’s AI health unit formed by ex-DeepMind co-founder Mustafa Suleyman ft.com/content/149296…

A pioneer who helped to make cell therapy what it is today.

AI's Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma - Yan Leyfman, MD oncodaily.com/insight/yan-le… #NasopharyngealCarcinoma #Immunotherapy #ImmuneOnc #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

We are very much looking forward to this upcoming episode of "Voices in Lymphoma: Women Shaping Care" with two inspiring Women in Lymphoma - [email protected]. Thank you, Carla Casulo, MD and Dr. Clémentine Sarkozy, for sharing your insights and inspiring the younger generations of women in medicine.

Meningioma remains the most common primary CNS tumor, yet treatment options for aggressive or recurrent cases are limited. A new study explores mesothelin-targeted CAR T-cell therapy as a potential solution. ✅ Mesothelin is expressed in a subset of meningiomas across all grades

🎥 MedNews Week x OncLive x Women in Lymphoma Present: 🌟 Voices in Lymphoma: Women Shaping Care 🌟 💡 Follicular Lymphoma: General Concept and First Line Strategies 🗓️ Tuesday, July 15 ⏰ 6:30 PM EST Join us for an empowering discussion led by two global experts shaping the

🎥 MedNews Week x OncLive x Women in Lymphoma Present: 🌟 Voices in Lymphoma: Women Shaping Care 🌟 💡 Follicular Lymphoma: General Concept and First Line Strategies 🗓️ Tuesday, July 15 ⏰ 6:30 PM EST Join us for an empowering discussion led by two global experts shaping the

🚨 First-in-Human Case Series: In Vivo CAR T for Multiple Myeloma A groundbreaking study introduces ESO-T01, a nanobody-targeted, immune-shielded lentiviral vector delivering BCMA-specific CAR T cells directly in vivo—bypassing the need for apheresis, manufacturing, or

🎗️ Oncology for the Non-Oncologist 🎗️ Thread: Oncology Emergencies You Can’t Miss Interns listen up - 🧵

🧠💥 Can macrophages revolutionize cancer immunotherapy? Macrophages naturally infiltrate tumors, reshape the TME, phagocytose cancer cells 🦠, and activate T cells ⚔️—making them powerful tools for next-gen therapy. 🚀 Enter CAR-Ms: Chimeric Antigen Receptor–engineered

⚕️Join Voices in Lymphoma: Women Shaping Care⚕️ 🩺Topic: Follicular Lymphoma - General Concepts & First Line Strategies 📆Tuesday, July 15 at 6:30PM EST MedNewsWeek is featuring Dr. Clementine Sarkozy & Dr. Carla Casulo Link: globalmeet.webcasts.com/starthere.jsp?…

🚨 3-Year TRANSFORM Trial Update 🚨 For 2L primary refractory/early relapsed LBCL, liso-cel 🧬 continues to outperform standard of care (SOC) 🧪 📊 Key Results (Median follow-up: 33.9 mo): 🟢 EFS: 29.5 mo (liso-cel) vs 2.4 mo (SOC) 🛡️ PFS: Not reached vs 6.2 mo 💪 3-yr PFS: